Equities research analysts predict that The Medicines Company (NASDAQ:MDCO) will report sales of $20.31 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for The Medicines’ earnings. The lowest sales estimate is $16.24 million and the highest is $26.80 million. The Medicines posted sales of $25.20 million during the same quarter last year, which suggests a negative year over year growth rate of 19.4%. The business is scheduled to announce its next earnings results on Tuesday, February 27th.
On average, analysts expect that The Medicines will report full-year sales of $20.31 million for the current year, with estimates ranging from $76.07 million to $86.70 million. For the next year, analysts expect that the company will report sales of $78.71 million per share, with estimates ranging from $12.03 million to $196.40 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for The Medicines.
A number of analysts have commented on MDCO shares. Zacks Investment Research lowered shares of The Medicines from a “hold” rating to a “sell” rating in a research note on Tuesday, December 26th. JPMorgan Chase & Co. restated an “overweight” rating and set a $45.00 price target on shares of The Medicines in a research note on Wednesday, January 24th. ValuEngine upgraded shares of The Medicines from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Guggenheim started coverage on shares of The Medicines in a research note on Monday, October 23rd. They set a “buy” rating and a $45.00 price target for the company. Finally, Chardan Capital restated a “buy” rating and set a $85.00 price target on shares of The Medicines in a research note on Wednesday, January 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $51.70.
In other news, Director Alexander J. Denner bought 170,000 shares of The Medicines stock in a transaction dated Wednesday, November 29th. The stock was purchased at an average price of $30.03 per share, for a total transaction of $5,105,100.00. Following the purchase, the director now directly owns 6,663 shares in the company, valued at approximately $200,089.89. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Clive Meanwell sold 136,250 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $27.24, for a total transaction of $3,711,450.00. Following the completion of the sale, the chief executive officer now owns 587,652 shares of the company’s stock, valued at approximately $16,007,640.48. The disclosure for this sale can be found here. Insiders own 8.22% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in shares of The Medicines in the 3rd quarter worth $171,000. SG Americas Securities LLC purchased a new position in shares of The Medicines in the 3rd quarter worth about $198,000. Ameritas Investment Partners Inc. boosted its holdings in shares of The Medicines by 4.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,058 shares of the company’s stock worth $230,000 after buying an additional 243 shares during the last quarter. HighTower Advisors LLC boosted its holdings in shares of The Medicines by 16.2% in the 2nd quarter. HighTower Advisors LLC now owns 6,754 shares of the company’s stock worth $258,000 after buying an additional 941 shares during the last quarter. Finally, Flinton Capital Management LLC boosted its holdings in shares of The Medicines by 75.4% in the 2nd quarter. Flinton Capital Management LLC now owns 7,038 shares of the company’s stock worth $267,000 after buying an additional 3,026 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: This news story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/11/zacks-brokerages-anticipate-the-medicines-company-mdco-will-announce-quarterly-sales-of-20-31-million.html.
About The Medicines
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.